Latest news with #Alector
Business Insider
14-06-2025
- Business
- Business Insider
Alector CFO Marc Grasso to depart, Neil Berkley appointed Interim CFO
Alector (ALEC) announced that its CFO, Marc Grasso, M.D., will conclude his tenure with the company, effective June 20 to pursue other opportunities. Neil Berkley the company's Chief Business Officer, will assume the role of Interim CFO while continuing in his current position. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Yahoo
03-06-2025
- Business
- Yahoo
Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2024, at 8:40 am ET. A live webcast of the fireside chat will be available on the 'Events & Presentations' page within the Investors section of the Alector website at A replay will be available on the Alector website for 90 days following the event. About AlectorAlector is a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of genetically validated programs that aim to remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector's product candidates seek to treat a range of indications, such as frontotemporal dementia, Alzheimer's disease, and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its next-generation product candidates and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit Alector Contacts: AlectorKatie Argot Partners (media)David Rosen646-461-6387alector@ Argot Partners (investors)Laura Perry212-600-1902alector@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
12-05-2025
- Business
- Business Insider
Analysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), Iovance Biotherapeutics (IOVA)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Axsome Therapeutics (AXSM – Research Report), Iovance Biotherapeutics (IOVA – Research Report) and Alector (ALEC – Research Report) with bullish sentiments. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Axsome Therapeutics (AXSM) Morgan Stanley analyst Vikram Purohit maintained a Buy rating on Axsome Therapeutics yesterday and set a price target of $190.00. The company's shares closed last Friday at $107.76. According to Purohit is a 1-star analyst with an average return of -4.1% and a 37.7% success rate. Purohit covers the Healthcare sector, focusing on stocks such as Recursion Pharmaceuticals, BioMarin Pharmaceutical, and Arcutis Biotherapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Axsome Therapeutics with a $176.07 average price target, a 61.7% upside from current levels. In a report issued on April 29, RBC Capital also maintained a Buy rating on the stock with a $193.00 price target. Wells Fargo analyst Yanan Zhu maintained a Buy rating on Iovance Biotherapeutics on May 9 and set a price target of $18.00. The company's shares closed last Friday at $1.75. According to Zhu has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -5.6% and a 26.4% success rate. Zhu covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Crispr Therapeutics AG, and Taysha Gene Therapies. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Iovance Biotherapeutics with a $13.83 average price target, representing a 612.9% upside. In a report issued on May 8, TD Cowen also maintained a Buy rating on the stock with a $5.00 price target. Alector (ALEC) BTIG analyst Thomas Shrader maintained a Buy rating on Alector on May 9 and set a price target of $5.00. The company's shares closed last Friday at $1.17. According to Shrader is a 2-star analyst with an average return of 0.2% and a 33.8% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Coya Therapeutics, Inc., Acumen Pharmaceuticals, and Arcturus Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alector with a $5.50 average price target, which is a 428.8% upside from current levels. In a report issued on May 8, TD Cowen also maintained a Buy rating on the stock.
Yahoo
10-05-2025
- Business
- Yahoo
Alector First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
Revenue: US$3.67m (down 77% from 1Q 2024). Net loss: US$40.5m (loss widened by 12% from 1Q 2024). US$0.41 loss per share (further deteriorated from US$0.39 loss in 1Q 2024). Our free stock report includes 3 warning signs investors should be aware of before investing in Alector. Read for free now. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue missed analyst estimates by 14%. Earnings per share (EPS) exceeded analyst estimates by 17%. Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are down 10.0% from a week ago. We should say that we've discovered 3 warning signs for Alector that you should be aware of before investing here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-05-2025
- Business
- Yahoo
Alector First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
Revenue: US$3.67m (down 77% from 1Q 2024). Net loss: US$40.5m (loss widened by 12% from 1Q 2024). US$0.41 loss per share (further deteriorated from US$0.39 loss in 1Q 2024). Our free stock report includes 3 warning signs investors should be aware of before investing in Alector. Read for free now. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue missed analyst estimates by 14%. Earnings per share (EPS) exceeded analyst estimates by 17%. Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are down 10.0% from a week ago. We should say that we've discovered 3 warning signs for Alector that you should be aware of before investing here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
